

Special Issue

The Clinical, Technological, and Scientific Progress of Boron Neutron Capture Therapy

Message from the Guest Editor

Boron neutron capture therapy (BNCT) has emerged as a clinically viable particle therapy, enabling tumor-selective irradiation based on molecular targeting. With the advent of accelerator-based neutron sources and advanced compound development, BNCT is now entering an era of practical medical application and broader social implementation. This Special Issue aims to collect cutting-edge research that accelerates the clinical, technological, and scientific progress of BNCT. We welcome studies from diverse disciplines, including physics, chemistry, biology, engineering, drug development, neutron dosimetry, and radiobiological effects. While boron-based approaches remain central, contributions exploring other neutron capture agents and novel concepts in neutron capture therapy (NCT) are also encouraged. The purpose of this Special Issue is to present new insights into the expanding frontiers of BNCT and its future role in precision radiation oncology. This Special Issue welcomes reviews as well as original research articles, which should be submitted by 15 September 2026.

Guest Editor

Prof. Dr. Shinji Kawabata
Laboratory of BNCT Advancement in Neuro-Oncology, Division of Surgery, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan

Deadline for manuscript submissions

15 September 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/257974

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)